Published in Clin Exp Immunol on November 01, 2007
Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol (2009) 1.75
Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol Cancer (2010) 1.28
Diminished IFN-gamma and IL-10 and elevated Foxp3 mRNA expression in the cervix are associated with CIN 2 or 3. Int J Cancer (2009) 0.98
The invisible enemy - how human papillomaviruses avoid recognition and clearance by the host immune system. Open Virol J (2012) 0.91
New Approaches to Immunotherapy for HPV Associated Cancers. Cancers (Basel) (2011) 0.89
Dysregulated expression of both the costimulatory CD28 and inhibitory CTLA-4 molecules in PB T cells of advanced cervical cancer patients suggests systemic immunosuppression related to disease progression. Pathol Oncol Res (2011) 0.87
Immune therapy for human papillomaviruses-related cancers. World J Clin Oncol (2014) 0.86
Increase of human papillomavirus-16 E7-specific T helper type 1 response in peripheral blood of cervical cancer patients after radiotherapy. Immunology (2008) 0.82
From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors. Clin Dev Immunol (2011) 0.80
Alterations of T-cell surface markers in older women with persistent human papillomavirus infection. Int J Cancer (2011) 0.79
An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy. PLoS One (2013) 0.78
Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia. Gynecol Oncol (2009) 0.77
Peripheral blood lymphocytes from low-grade squamous intraepithelial lesions patients recognize vaccine antigens in the presence of activated dendritic cells, and produced high levels of CD8 + IFNγ + T cells and low levels of IL-2 when induced to proliferate. Infect Agent Cancer (2012) 0.76
High-risk oncogenic HPV genotype infection associates with increased immune activation and T cell exhaustion in ART-suppressed HIV-1-infected women. Oncoimmunology (2016) 0.75
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 40.32
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol (2005) 13.03
CD4+CD25high regulatory cells in human peripheral blood. J Immunol (2001) 11.25
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol (1999) 7.60
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol (2002) 6.60
Mechanisms of suppression by suppressor T cells. Nat Immunol (2005) 5.52
Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res (2001) 5.48
Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol (2005) 5.43
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest (2005) 5.30
Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol (2004) 3.61
Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol (2004) 3.58
Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res (2003) 3.44
POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer (2004) 2.89
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res (2005) 2.78
Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res (2003) 2.45
Radical hysterectomy for stage IB1 vs IB2 carcinoma of the cervix: does the new staging system predict morbidity and survival? Gynecol Oncol (1996) 2.14
Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res (2004) 1.90
Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol (2004) 1.81
Differentiation and expansion of T cells with regulatory function from human peripheral lymphocytes by stimulation in the presence of TGF-{beta}. J Immunol (2005) 1.79
CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol (2003) 1.61
Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res (2004) 1.50
Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+ CD25+ regulatory T cell-depleted mice. Cancer Res (2005) 1.48
Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res (2003) 1.40
CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood (2005) 1.38
Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J Immunol (2001) 1.36
Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma. Blood (2005) 1.16
Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. Cancer Res (2000) 1.14
The role of suppressor T cells in regulation of immune responses. J Allergy Clin Immunol (2002) 1.12
T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. Br J Cancer (2005) 1.08
HPV infections and immunosuppression. Clin Dermatol (1997) 0.95
Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia. Int J Cancer (2006) 0.94
Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients. Gynecol Oncol (2004) 0.92
Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma. Cancer (2004) 0.89
Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Gene Ther (2005) 0.89
Enhancement of human papilloma virus type 16 E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia. Int J Cancer (2006) 0.84
Human papillomavirus type 16-specific T cell responses and their association with recurrence of cervical disease following treatment. J Gen Virol (2003) 0.81
B lymphocytes secrete antigen-presenting vesicles. J Exp Med (1996) 11.53
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol (1989) 8.32
Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol (1992) 7.92
Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med (1995) 7.26
Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med (1993) 7.21
Programmed death of T cells in HIV-1 infection. Science (1992) 5.63
Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med (1998) 5.08
Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest (1994) 4.63
Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet (1989) 4.19
HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS (1992) 3.91
Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med (2000) 3.70
Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science (1993) 3.62
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer (2011) 3.45
T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat Immunol (2000) 3.33
Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J Infect Dis (1992) 3.16
Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med (1997) 3.08
Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase. Nature (1987) 2.72
Functional and phenotypic evidence for a selective loss of memory T cells in asymptomatic human immunodeficiency virus-infected men. J Clin Invest (1990) 2.51
Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV-1 phenotype. AIDS (1992) 2.35
D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene (1991) 2.21
T cell telomere length in HIV-1 infection: no evidence for increased CD4+ T cell turnover. Science (1996) 2.12
Regulatory properties of LFA-1 alpha and beta chains in human T-lymphocyte activation. Nature (1988) 2.09
Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol (1997) 2.07
High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: evidence for impaired CTL effector function. Eur J Immunol (2001) 1.99
Selective loss of T cell functions in different stages of HIV infection. Early loss of anti-CD3-induced T cell proliferation followed by decreased anti-CD3-induced cytotoxic T lymphocyte generation in AIDS-related complex and AIDS. Eur J Immunol (1990) 1.99
AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS (1997) 1.97
Lack of T cell dysfunction and programmed cell death in human immunodeficiency virus type 1-infected chimpanzees correlates with absence of monocytotropic variants. J Infect Dis (1993) 1.95
Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV p24gag. Virology (1989) 1.91
Reduced naive and increased activated CD4 and CD8 cells in healthy adult Ethiopians compared with their Dutch counterparts. Clin Exp Immunol (1999) 1.88
Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia (2006) 1.88
T cell receptor excision circles as markers for recent thymic emigrants: basic aspects, technical approach, and guidelines for interpretation. J Mol Med (Berl) (2001) 1.86
Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS (1993) 1.85
Germline mutations of EXO1 gene in patients with hereditary nonpolyposis colorectal cancer (HNPCC) and atypical HNPCC forms. Gastroenterology (2001) 1.84
A potential role of macrophage activation in the treatment of cancer. Crit Rev Oncol Hematol (2002) 1.81
Proliferation-dependent HIV-1 infection of monocytes occurs during differentiation into macrophages. J Clin Invest (1992) 1.81
The CD27- subset of peripheral blood memory CD4+ lymphocytes contains functionally differentiated T lymphocytes that develop by persistent antigenic stimulation in vivo. Eur J Immunol (1992) 1.79
In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol (1993) 1.79
OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol (2001) 1.75
Evidence that human CD8+CD45RA+CD27- cells are induced by antigen and evolve through extensive rounds of division. Int Immunol (1999) 1.75
Associations between HLA frequencies and pathogenic features of human immunodeficiency virus type 1 infection in seroconverters from the Amsterdam cohort of homosexual men. J Infect Dis (1994) 1.75
Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2000) 1.73
Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia (2006) 1.72
Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood (1995) 1.71
hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene (1997) 1.67
Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2010) 1.66
Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis (1995) 1.65
Biochemical and functional characteristics of the human leukocyte membrane antigen family LFA-1, Mo-1 and p150,95. Eur J Immunol (1985) 1.64
Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood (1998) 1.63
Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users compared with homosexual men. AIDS (1995) 1.63
Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with disease progression. J Virol (1999) 1.63
Consistent associations of HLA class I and II and transporter gene products with progression of human immunodeficiency virus type 1 infection in homosexual men. J Infect Dis (1999) 1.60
EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia (2012) 1.60
IL-12-induced IL-10 production by human T cells as a negative feedback for IL-12-induced immune responses. J Immunol (1996) 1.54
Human CD8+ T lymphocytes can be divided into CD45RA+ and CD45RO+ cells with different requirements for activation and differentiation. J Immunol (1991) 1.54
T-cell dysfunction in HIV infection: anergy due to defective antigen-presenting cell function? Immunol Today (1993) 1.54
Rapid disease progression in human immunodeficiency virus type 1-infected individuals with adverse reactions to trimethoprim-sulfamethoxazole prophylaxis. Clin Infect Dis (1997) 1.51
Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy. Nat Med (1998) 1.50
Both Fc receptors and lymphocyte-function-associated antigen 1 on human T gamma lymphocytes are required for antibody-dependent cellular cytotoxicity (killer cell activity). Eur J Immunol (1984) 1.48
Tumour infiltration depth ≥4 mm is an indication for an elective neck dissection in pT1cN0 oral squamous cell carcinoma. Oral Oncol (2011) 1.48
Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses. J Gen Virol (1998) 1.47
Evidence that leukocyte function-associated antigen-1 is involved in recirculation and homing of human lymphocytes via high endothelial venules. J Immunol (1988) 1.47
Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection. J Infect Dis (1998) 1.46
Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer (1999) 1.44
Changes in the composition of circulating CD8+ T cell subsets during acute epstein-barr and human immunodeficiency virus infections in humans. J Infect Dis (2000) 1.44
Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus-1 (HIV-1)-infected men. J Clin Immunol (1990) 1.42
Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains. AIDS (2001) 1.42
Productive HIV-1 infection of macrophages restricted to the cell fraction with proliferative capacity. EMBO J (1994) 1.41
Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med (1997) 1.40
Epstein-Barr virus-specific cytotoxic T cell responses in HIV-1 infection: different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma. J Clin Invest (1997) 1.39
[Ethiopia-Netherlands AIDS research project]. Ned Tijdschr Geneeskd (2001) 1.38
Programmed death of T cells in human immunodeficiency virus infection. No correlation with progression to disease. J Clin Invest (1994) 1.36
Human immunodeficiency virus infection down-regulates HLA class II expression and induces differentiation in promonocytic U937 cells. J Clin Invest (1987) 1.36
Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood (1995) 1.34
Decreased accessory cell function by human monocytic cells after infection with HIV. J Immunol (1988) 1.34
The dominant source of CD4+ and CD8+ T-cell activation in HIV infection is antigenic stimulation. J Acquir Immune Defic Syndr (2000) 1.29
A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Int J Cancer (2012) 1.28
Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. J Infect Dis (1999) 1.28
Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer (2001) 1.28
Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res (2001) 1.28
γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia. Leukemia (2013) 1.28
Single cell analysis of IL-4 and IFN-gamma production by T cells from HIV-infected individuals: decreased IFN-gamma in the presence of preserved IL-4 production. J Immunol (1996) 1.28
Human immunodeficiency virus infection studied in CD4-expressing human-murine T-cell hybrids. Virology (1989) 1.26
Lymphoproliferative response to HIV type 1 p24 in long-term survivors of HIV type 1 infection is predictive of persistent AIDS-free infection. AIDS Res Hum Retroviruses (1999) 1.24
Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS (1998) 1.24
Induction of immunoglobulin synthesis by interleukin 2 is T4+/T8- cell dependent. A role for interleukin 2 in the pokeweed mitogen-driven system. Eur J Immunol (1985) 1.24
Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood (2000) 1.24
Expression of cyclin D1 and EMS1 in bladder tumours; relationship with chromosome 11q13 amplification. Oncogene (1996) 1.24
Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst (1995) 1.21
Clonal analysis of functionally distinct human CD4+ T cell subsets. J Exp Med (1988) 1.21
Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol (1996) 1.21